-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
WCLC 2020 Archive
-
Finding the Benefits of the Virtual World: A Conversation with Dr. Heather Wakelee
Heather Wakelee, MD, is the President-Elect of the IASLC and will assume presidential responsibilities at the 2021 WCLC in September. She is the Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. She is also the principal investigator of numerous clinical trials and lead investigator for the…
-
Interim Chief Scientific Officer Dr. Giorgio Scagliotti Brings Vast IASLC Knowledge to Role
With a long history in leadership positions at the IASLC, Dr. Scagliotti is fully prepared to help guide the society’s scientific projects through a transition period. Dr. Scagliotti, is professor of medical oncology at the University of Turin School of Medicine, Italy, where he is also a member of the administrative board. He is also…
-
Prof. Caroline Dive Honored with Mary J. Matthews Pathology/Translational Research Award for Work with CTCs
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Director of the CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, has been recognized by the IASLC with the Mary J. Matthews Pathology/Translational Research Award. The award recognizes an IASLC scientist for a lifetime achievement in pathology and translational research of thoracic malignancies. “I am utterly delighted and…
-
Dr. Pan-Chyr Yang Honored by IASLC for Contributions to Lung Cancer Prevention
Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan, will be recognized by the International Association for the Study of Lung Cancer (IASLC) with the Joseph W. Cullen Prevention/Early Detection Award at the fully virtual IASLC 2020 World Conference on Lung Cancer (WCLC). This award recognizes…
-
Paul A. Bunn, Jr., Scientific Award to Dr. Joan H. Schiller
Breath is life. We depend so much on our ability to breathe with ease but, for patients with lung cancer, that is no small task. For her entire career, Joan H. Schiller, MD, FASCO helped patients breathe easier and enjoy a better quality of life. Dr. Schiller has helped to break the taboo of talking…
-
A New Year’s Resolution to Promote the Use of Patient-Sensitive Language
In 2021, people living with lung cancer and their caregivers will likely be attending virtual oncology conferences such as the 2020 WCLC and making deep dives into research in record numbers. Due to improvements in lung cancer diagnosis and treatment, more patients with lung cancer are living longer and better, thus becoming increasingly involved in…
-
WCLC Conference Chairs Offer Insights on The New All-Virtual Program, The Year Ahead
The Chairs of the 2020 World Conference on Lung Cancer, all based in Asia, had originally designed a live program to be hosted in Singapore. The outbreak of COVID-19 forced Drs. Yi-Long Wu, Ross Soo, and Daniel Tan to not only reschedule the live event to a virtual program but to also re-imagine the program.…
-
2020 Adi F. Gazdar IASLC Merit Award Recipient: Dr. Alex A. Adjei
Alex A. Adjei, MD, PhD, is a Professor of Oncology and Professor of Pharmacology in the Mayo College of Medicine. He has had a passion for drug development in cancer, as well as for mentoring the next generation of specialists during his multifaceted career. For his many accomplishments in cancer drug development, Dr. Adjei has…
-
Should We Delay Lung Cancer Screening During the COVID-19 Pandemic?
To address the issue of low-dose CT screening, during the COVID-19 pandemic, for lung cancer and management of both screen-detected nodules and incidentally detected nodules, various eminent organizations and expert groups have created guidance documents.1-4 The overarching principal guiding safe resumption of nonurgent imaging is clearly stated in a separate document by the American College…
-
Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey
The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each patient’s disease.1,2 The majority of these novel therapies are either immunotherapies or molecularly targeted agents. Identification of the best therapeutic option for every patient before…